Characterization of THLE-cytochrome P450 (P450) cell lines: Gene expression background and relationship to P450-enzyme activity

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2054-2058

  Soltanpour, Yalda ^a,c   Hilgendorf, Constanze ^a   Ahlström, Marie M ^a   Foster, Alison J ^b   Kenna, J Gerry ^b   Petersen, Anne ^c   Ungell, Anna Lena ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; MESSENGER RNA; NUCLEAR HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN THLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER TOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION; HUMANS; LIVER; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 84867682745     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045815     Document Type: Article

References (27)

1. Antoine DJ, Williams DP, and Park BK (2008) Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol 4:1415-1427.
2. Antolino-Lobo I, Meulenbelt J, van den Berg M, and van Duursen MB (2011) A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity. Veterinary Quarterly 31:193-205.
3. Behrens I, Kamm W, Dantzig AH, and Kissel T (2004) Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J Pharm Sci 93:1743-1754. (Pubitemid 38823702)
4. Benbow JW, Aubrecht J, Banker MJ, Nettleton D, and Aleo MD (2010) Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. Toxicol Lett 197:175-182.
5. Cai SY and Boyer JL (2006) FXR: a target for cholestatic syndromes? Expert Opin Ther Targets 10:409-421.
6. Dambach DM, Andrews BA, and Moulin F (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33:17-26. (Pubitemid 40216800)
7. Foster AJ, Greer ML, Coates R, Smith TJD, and Kenna JG (2010) In vitro investigation of the role of cyp dependent metabolism in drug hepatotoxicity using the THLE-CYP cell panel. Toxicology 278:355-356.
8. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
9. Greer ML, Barber J, Eakins J, and Kenna JG (2010) Cell based approaches for evaluation of drug-induced liver injury. Toxicology 268:125-131.
10. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, et al. (2008) Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-396.
11. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
12. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340. (Pubitemid 47121774)
13. Hozoji M, Munehira Y, Ikeda Y, Makishima M, Matsuo M, Kioka N, and Ueda K (2008) Direct interaction of nuclear liver X receptor-beta with ABCA1 modulates cholesterol efflux. J Biol Chem 283:30057-30063.
14. Kalgutkar AS and Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
15. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
16. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253. (Pubitemid 39410908)
17. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
18. Pachkoria K, Lucena MI, Molokhia M, Cueto R, Carballo AS, Carvajal A, and Andrade RJ (2007) Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2:97-112. (Pubitemid 46812950)
19. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, et al. (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292-306.
20. Pfaffl MW, Tichopad A, Prgomet C, and Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excelbased tool using pair-wise correlations. Biotechnol Lett 26:509-515. (Pubitemid 38448421)
21. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, and Trump BF (1993) Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. PNAS 90:5123-5127. (Pubitemid 23182989)
22. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009a) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie." Drug Metab Dispos 37:2255-2261.
23. Riches Z, Bloomer J, Patel A, Nolan A, and Coughtrie M (2009b) Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation. Xenobiotica 39:374-381.
24. Stahl S, Davies MR, Cook DI, and Graham MJ (2008) Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38:725-777.
25. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, and Artursson P (2004) Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci 21:69-75. (Pubitemid 38050205)
26. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, and Kenna JG (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65-71.
27. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, et al. (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25:1616-1632.